JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 38 No. 5 682-686
© 1997 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Söderlund, V.
Right arrow Articles by Jacobsson, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Söderlund, V.
Right arrow Articles by Jacobsson, H.

Comparison of Technetium-99m-MIBI and Technetium-99m-Tetrofosmin Uptake by Musculoskeletal Sarcomas

Veli Söderlund, Cathrine Jonsson, Henrik C.F. Bauer, Otte Brosjö and Hans Jacobsson

Departments of Diagnostic Radiology, Hospital Physics and Orthopedic Surgery, Karolinska Hospital, Stockholm, Sweden

Correspondence: For correspondence or reprints contact: Hans Jacobsson, MD, Dept. of Diagnostic Radiology, Karolinska Hospital, S-171 76 Stockholm, Sweden.

ABSTRACT

Technetium-99m-MIBI was initially developed for heart studies but it can also be used to depict tumors, predict multidrug resistance and evaluate chemotherapy. Recently, 99mTc-tetrofosmin, which exhibits similar physical properties, has been launched for heart studies. Tumor uptake and prediction of multidrug resistance have also been reported regarding the latter tracer. A comparison of these two tracers regarding the detectability of musculoskeletal sarcoma has been made. Methods: Twenty patients with musculoskeletal sarcoma of the extremities or pelvis underwent planar examination after the administration of 99mTc-MIBI and 99mTc-tetrofosmin with an interval of 2–7 days. The tumor activity was compared with one ipsilateral and one contralateral background region. Results: There was a small, but not significant, difference in favor of 99mTc-MIBI with regard to both background regions. Conclusion: Technetium 99mTc-MIBI and 99mTc-tetrofosmin can both be used to visualize musculoskeletal sarcomas. The choice may depend on which agent is used routinely for myocardial studies in the laboratory.

Key Words: musculoskeletal sarcoma • technetium-99m-MIBI • technetium-99m-tetrofosmin • tumor imaging






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1997 by the Society of Nuclear Medicine.